Syncona has invested €30 million (£25.7 million) in iOnctura, an innovative, clinical-stage, small molecule company combating neglected and hard-to-treat cancers.
iOnctura represents an opportunity to invest in a clinical-stage company and to take its lead programme, roginolisib, through to late-stage clinical development. This is in line with Syncona’s strategy to focus capital deployment on clinical-stage assets or assets approaching clinical entry.
